Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Early Data Suggest Novo Nordisk's Long-Acting Insulin DegludecOn Par With Sanofi's Lantus

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Novo Nordisk has made a good start for its ultra-long acting insulin Degludec, with much-anticipated Phase II data released at the American Diabetes Association annual scientific sessions June 25 showing that Degludec is as good as Sanofi-Aventis's Lantus (insulin glargine). However, to unseat the market leader, the Danish firm will need to show its insulin analog is superior in either maintaining blood glucose control or reducing the incidence of hypoglycemia

You may also be interested in...

Sanofi-Aventis Takes Rights to Metabolex's Diabetes Compound

As it continues to diversify away from its juggernaut Lantus, Sanofi takes a chance on a potential first-in-class drug not yet through Phase II.

Novo Nordisk's GLP-1 Victoza Off To A Good Start

New head-to-head study against popular oral Januvia could bolster case for use as a second-line agent in diabetes, company says.

Novo Nordisk: Riding High on Diabetes

Novo Nordisk is confident that it can continue to generate strong growth from its leading diabetes franchise. Having exited oral anti-diabetics, it's betting on further innovation in insulin and on a strong entry into the GLP-1 analog space.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts